Korean study monitors new multiple myeloma drug in Real-World use
NCT ID NCT06581848
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is monitoring the safety and effectiveness of the drug Elranatamab in 150 Korean adults with multiple myeloma that has returned or not responded to at least three prior treatments. Researchers are tracking side effects and how well the drug controls the cancer in everyday clinical practice. The goal is to gather real-world data to better understand the drug's risks and benefits.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer
Seoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- A guided path back to work after blood cancer: a trial tests the impact